Table 4.
Comparison between the high LDH and low LDH groups (N = 341)
| Variable | LDH <271 (N = 251) N (%) |
LDH ≥271 (N = 90) N (%) |
P-value |
|---|---|---|---|
| Age | |||
| <65 years | 144 (57.4) | 51 (56.7) | 0.908 |
| ≥65 years | 107 (42.6) | 39 (43.3) | |
| Sex | |||
| Male | 123 (49.0) | 43 (47.8) | 0.842 |
| Female | 128 (51.0) | 47 (52.2) | |
| Primary tumor site | |||
| Gallbladder | 99 (39.8) | 28 (31.5) | 0.154 |
| Distal bile duct | 64 (25.7) | 34 (38.2) | |
| Hilar | 58 (23.3) | 17 (19.1) | |
| Intrahepatic | 28 (11.2) | 10 (11.2) | |
| Depth of tumor invasion | |||
| T1 | 20 (8.4) | 3 (3.4) | 0.064 |
| T2 | 102 (42.7) | 30 (33.7) | |
| T3 | 105 (43.9) | 53 (59.6) | |
| T4 | 12 (5.0) | 3 (3.4) | |
| Lymph node status | |||
| Negative | 170 (70.2) | 53 (58.9) | 0.050 |
| Positive | 72 (29.8) | 37 (41.1) | |
| Metastasis | |||
| Negative | 219 (90.5) | 80 (88.9) | 0.664 |
| Positive | 23 (9.5) | 10 (11.1) | |
| Seventh UICC TNM stage | |||
| I | 30 (12.7) | 11 (12.4) | 0.752 |
| II | 104 (44.1) | 34 (38.2) | |
| III | 69 (29.2) | 31 (34.8) | |
| IV | 33 (14.0) | 13 (14.6) | |
| Histologic differentiation | |||
| Well and moderately differentiated | 113 (48.5) | 38 (43.7) | 0.442 |
| Poorly differentiated | 120 (51.5) | 49 (56.3) | |
| Lymphovascular invasion | |||
| Negative | 224 (91.1) | 72 (80.9) | 0.010 |
| Positive | 22 (8.9) | 17 (19.1) | |
| Perineural invasion | |||
| Negative | 135 (54.9) | 37 (41.6) | 0.031 |
| Positive | 111 (45.1) | 52 (58.4) | |
| Resection margin | |||
| Negative | 194 (78.9) | 64 (71.9) | 0.182 |
| Microscopic positive | 52 (21.1) | 25 (28.1) | |
| Hemoglobin g/L, median (IQR) | 125.00 (114.00–134.75) | 125 (111.5–137.0) | 0.426 |
| CEA ng/mL, median (IQR) | 3.10 (2.06–5.22) | 3.80 (2.30–5.50) | 0.503 |
| CA19-9 U/mL, median (IQR) | 68.15 (19.35–336.90) | 132.50 (55.60–707.40) | 0.192 |
Note: Data in bold indicates P < 0.05.
Abbreviations: LDH, lactic dehydrogenase; UICC, Union for International Cancer Control; TNM, tumor node metastasis; IQR, interquartile range; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9.